Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025

Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025

Analysis of revenues and R&D prospects for those eye drugs – you explore potentials What’s the future for treating disorders of the retina? Visiongain’s updated study forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies and opportunities.

That report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead find what’s happening for those eye medicines. Discover, from 2015, what’s possible.

There gain technological, clinical and commercial outlooks. Read on to explore those ophthalmic pharmaceuticals and see what future revenues they could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions

There explore prospects for companies developing, producing and marketing drugs for wet age-related macular degeneration (AMD or ARMD), dry AMD, diabetic retinopathy (DR) and other rear eye disorders. Discover present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Explore research and development too, seeing prospects. Also get 42 tables, 46 charts and two research interviews.

That survey also covers geographic atrophy (GA), diabetic macular oedema/edema (DME), proliferative and non-proliferative diabetic retinopathy (PDR and NPDR) and retinal vein occlusion (RVO). Avoid missing out on original data and discussions to help your work.

Ophthalmic technology – find sales growth opportunities and how to help your work

Stay ahead, then, in knowledge. Our study’s purpose is to benefit your research, analyses and decisions.

There find the most promising and lucrative treatments for neovascularisation and other retinal diseases from 2015.

The future holds great promise for organisations treating those rear eye disorders. Discover the progress and high gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.

And the following sections explain what you get in that new investigation.

Forecasting the world market and segments for medicines treating retinal disorders

What’re the secrets of that technology's progress? What’s its potential? Find in our report overall world revenue to 2025 for retinal medicines – existing, emerging and expected drugs.

Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:

  • Wet age-related macular degeneration (wAMD)
  • Dry AMD (dAMD)
  • Diabetic retinopathy (DR)
  • Other retinal diseases (grouped forecast).
Where lie the best prospects? You assess outlooks for revenue expansion, seeing where you can gain. And also investigate competitors’ actions and prospects.

There hear what’s happening for those ophthalmic medicines and discover where the money lies. Benefit your reputation for technological and commercial insight there, increasing your authority.

You also find sales predictions by product, exploring how they can succeed.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?

How will individual retinal medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of five prominent brands:
  • Lucentis
  • Eylea
  • Avastin
  • Visudyne
  • Jetrea.
There you discover how high sales can go, finding agents and years with highest predicted revenues. Also examine competition. That way you investigate what’s happening, understanding challenges, trends, competitors and opportunities.

Single and combination treatments hold importance. Our report explains. That work also shows you geographical predictions, by country.

Healthcare in national markets – what outlooks for retinal medical sales?

Advances in biotechnology and pharmaceuticals expand use of drugs to treat back-of-eye impairments and vision loss. Discover those technologies’ international sales prospects.

Our work shows you individual revenue forecasts to 2025 for 11 national markets:
  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).
There find countries with highest revenues and potential growth. You explore outlooks for treating ocular problems, serving doctors’ and patients’ needs. Assess opportunity and ways to help people retain eyesight. Discover, then, what’s possible for you and your organisation.

You also examine developments leading to novel treatments.

R&D for those ophthalmic agents – developmental trends, innovations and progress

There you also investigate R&D, appraising technological, clinical and commercial possibilities.

In our study explore research and development in slowing vision loss and restoring sight. You examine these advances and others:
  • Combination therapies, including neovascularisation disrupters
  • Angiogenesis inhibition by blocking pericyte recruitment
  • Anti-inflammatory mechanisms (inc. corticosteroids)
  • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
  • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.
Explore other agents and possibilities, too, including these:
  • Oligonucleotides and siRNA therapy
  • Anti-integrin oligopeptide treatment
  • Complement factor inhibition and serotonin modifiers
  • Angiotensin receptor blockers and converting enzyme inhibitors
  • Biosimilars and other follow-on biologicals and next generation therapeutics
  • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.
That R&D holds strength, variety and promise. See what’s possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.

There you investigate progress, assessing that industry’s participants and their futures.

Companies and overall 2019 market value – what revenues possible?

Our analyses forecast the world market for retinal drugs will reach $12.5bn in 2019. It will achieve strong revenue expansion from 2015 to 2025. You find how high sales can go.

You also see what companies hold most potential. Examine eye drug developers, producers and marketers, including these firms:
  • Roche
  • Novartis
  • Bayer
  • Regeneron
  • Allergan
  • Valeant.
You find 160 organisations mentioned. Also get two interviews with a company in that industry. Discover what the future holds for treating disorders of the retina.

Ways Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 helps

So our new investigation benefits your work in six main ways, helping you stay ahead:
  • Revenues for retinal disease treatments to 2025 – assess that overall world drugs market’s potential and get forecasted revenues for treating wet age-related macular degeneration (wAMD), dry AMD, diabetic retinopathy (DR) and other disorders
  • Products’ sales to 2025 – discover predicted revenues of Lucentis, Eylea, Avastin, Visudyne and Jetrea, seeing how those medicines can compete and succeed
  • National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth
  • R&D activities – see progress, trends and prospects in that ophthalmic research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinions – examine participants, including Roche, Novartis, Bayer, Regeneron and Allergan, and get two exclusive interviews, helping your reputation for insight and staying ahead
  • Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.
That survey, by our in-house UK-based analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. It shows information you find nowhere else.

Discover predictions for rear-eye medicines, getting information to help you now

With our independent analyses explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that data means you’re less likely to fall behind in knowledge or miss opportunity. Through your choice find how you could save time and effort, also benefiting your authority and results.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.

Companies Listed

Abbott Laboratories
Advanced Cell Technology (now Ocata Therapeutics)
Aldexa (previously Neuron Systems Inc.)
Alimera Sciences
Alkeus Pharmaceuticals
Allegro Ophthalmics
American Academy of Ophthalmology
American Society of Retina Specialists
Ampio Pharmaceuticals
Apellis Pharmaceuticals
Applied Genetic Technologies
Association for Research in Vision and Ophthalmology (ARVO)
Atlantis Pharma
ATON Pharma
Autorità Garante della Concorrenza e del Mercato (Italian Competition Authority)
Autorité de la concurrence (French Competition Authority)
Avalanche Biotechnologies
Bayer Yakuhin (Bayer subsidiary)
Biogen Idec
Biovail Corporation
Bristol-Myers Squibb
Casey Eye Institute at Oregon Health and Science University
Cell Cure Neurosciences (a subsidiary of BioTime)
Cellular Dynamics International
Center for iPS Cell Research and Application
Chengdu Kanghong Biotech
China Food and Drug Administration
Colby Pharmaceutical
Cochrane Collaboration
Columbia University
Eli Lilly
Elseiver Business Intelligence
Emory University
ES Cell International
European Court of Justice
European Medicines Agency (EMA)
EyeGate Pharmaceuticals
Food and Drug Administration (US FDA)
ForSight Labs
ForSight VISION4
Gene Signal
General Medical Council (GMC, UK)
Gerot Lannach
GlaxoSmithKline (GSK)
Human Genome Sciences
iCo Therapeutics
Icon Bioscience
Innovations in Sight
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG, Germany) International Diabetes Foundation
Institute of Ocular Pharmacology
iPS Academia Japan
ISTA Pharmaceuticals
Kaplan Medical Center
Ludwig-Maximilians - University of Munich
Mayo Clinic
MEDARVA Foundation
Merck & Co.
Ministry of Health, Labour and Welfare (Japan)
Molecular Partners
Mystic Pharmaceuticals
National Eye Institute (NEI, US)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Natur Produk
Neuron Systems Inc. (now Aldexa)
Novagali Pharma
Novo Nordisk
Novo Ventures
Numoda Capital Innovations
Oakwood Laboratories
Ocata Therapeutics
Ohr Pharmaceutical
Oklahoma Medical Research Foundation
OncoCyte (a subsidiary of BioTime)
Ophthotech Corporation
Ora Bio
OrthoCyte (a subsidiary of BioTime)
Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES, Austria)
Othera Pharmaceuticals
Otsuka Pharmaceutical
Oxford BioMedica
Paloma Pharmaceuticals
Palomid Pharmaceuticals
PDL BioPharma
Pedinol Pharmacal
Pele Nova Biotecnologica
Potentia Pharmaceuticals
Probiotica Laboratorios
Progen Pharmaceuticals
Purdue University
Quark Pharmaceuticals
ReCyte Therapeutics (a subsidiary of BioTime)
Retina Macula Institute
RetroSense Therapeutics
ReVision Therapeutics
Riken Institute
Santen Pharmaceuticals
Sanwa Kagaku Kenkyusho
SARcode Bioscience
Senju Pharmaceutical
Singapore National Eye Centre
Sirion Therapeutics
Sirna Therapeutics
Stemedica Cell Technologies
SV Life Sciences
Symphony ViDA
Teva Pharmaceutical Industries
Third Rock Ventures
University of Kentucky College of Medicine
University of Kyoto
University of Virginia
Valeant Pharma
Vitreoretinal Technologies
World Health Organization (WHO)
Xcovery Vision

1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Overview of the AMD and Other Retinal Diseases Market, 2014-2025
2.1 Market to Make Rapid Strides to 2025
2.2 Lucentis Still Holds Over 60% of the Total Market
2.2.1 Novartis the Leading Presence in the Market
2.3 Which are the Most Significant Disease Areas for the Market?
2.3.1 Nearly 200 Million People with AMD?
2.3.2 Over 100 Million with DR
2.3.3 First RVO Estimates Suggest Patient Population of 16 Million
2.3.4 Wet AMD Still the Main Source of Revenues in the Market
2.4 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
2.5 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
2.6 DR: Coming Into Clinical Focus, with DME the Main Target
2.7 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
2.8 Projections for All Segments, 2014-2025
3. Approved Products in the AMD and Other Retinal Diseases Market, 2014-2025
3.1 Will the Current Products Dominate the Market Through 2025?
3.2 Lucentis: The Market Leader, But For How Long?
3.2.1 Shadow of Avastin Still Hangs Over Lucentis
3.2.2 CATT Study Results: Clinical Differences Still Have Yet to Emerge
3.2.3 Eylea: The Bigger Threat to Lucentis?
3.2.4 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
3.2.5 Improving Cost and Compliance for Lucentis
3.2.6 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
3.2.7 Lucentis Revenue Forecast 2014-2025
3.3 Eylea: Pretender to the Throne?
3.3.1 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
3.3.2 First Wave of Eylea’s Expansion Finally Beginning to Break?
3.3.3 Into DME and Other New Indications
3.3.4 Zaltrap Targeting Solid Tumour Markets
3.3.5 How Far Can Eylea’s Momentum Carry It?
3.3.6 Eylea Revenue Forecast 2014-2025
3.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
3.4.1 Judicial Review Averted in the UK by Price Adjustment
3.4.2 Multiple Attempts to Block Off-Label Avastin Since 2007
3.4.3 Roche and Novartis Challenge CATT’s Headline Conclusions
3.4.4 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
3.4.5 Will Anything Dislodge Avastin from its Central Position?
3.4.6 Avastin Revenue Forecast, 2014-2025
3.5 Visudyne (Valeant/Novartis): Declining Sales Throughout the Forecast Period
3.5.1 Visudyne Revenue Forecast, 2014-2025
3.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
3.6.1 Jetrea Revenue Forecast, 2014-2025
4. Wet AMD Segment, 2014-2025
4.1 Eylea: The Segment’s Biggest Short-Term Driver
4.2 Pipeline for wAMD: The Leading Candidates
4.3 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
4.3.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
4.3.2 Ophthotech Goes Public to Fund Phase 3 Effort
4.3.3 Ophthotech Partners with Novartis for Fovista
4.3.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
4.3.5 The Move toward Combination Therapies
4.4 Other Growth Factor Targets in the Pipeline
4.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
4.4.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
4.4.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
4.4.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
4.5 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
4.5.1 A Chinese Competitor: Where Will Conbercept Fit In?
4.5.2 Binding Affinity Comparable to Eylea
4.6 Do We Need New Anti-VEGFR Agents or Delivery Systems?
4.6.1 AGN-150998 DARPin (Allergan): Novel Protein With Extended Half-Life
4.6.2 ESBA 1008 (Alcon): Single-Chain Monoclonal Antibody Fragment
4.6.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
4.6.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
4.6.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
4.6.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
4.7 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
4.7.1 Verisome System and IBI-30089 (Icon Bioscience)
4.7.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
4.8 Other Targets Under Investigation in wAMD Drug Development
4.8.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
4.8.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
4.8.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
4.8.4 First Ophthalmic Complement Factor Inhibitor, AL-78898A (Alcon), Misses Primary Endpoint
4.8.5 Factor C5: A More Promising Target Addressed by ARC1905 Aptamer (Ophthotech) and LFG316 (Novartis)
4.8.6 Integrins: Another Blockable Component of the Neovascularisation Cascade?
4.8.7 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
4.8.8 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
4.8.9 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
4.8.10 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
4.8.11 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
4.9 Regenerative Medicine Approaches
4.9.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
4.9.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
4.9.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
5. Dry AMD Segment, 2014-2025
5.1 Dry AMD Segment to Emerge in the Forecast Period
5.2 Who Will Achieve the Big Breakthrough in Dry AMD?
5.3 MC-1101 (MacuCLEAR): Leading the Pack?
5.3.1 Increasing Choroidal Blood Flow with Repurposed Product
5.3.2 Novel Endpoints in Phase 3 Study
5.3.3 Can MacuCLEAR Make It?
5.4 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
5.4.1 Data Expected in July 2016
5.4.2 Other Visual Cycle Modulators
5.5 High Hopes for Complement Inhibition in Dry AMD
5.5.1 Lampalizumab (Roche): The Big News of ARVO 2013 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
5.5.2 AL-78898A (Alcon): Phase 2 Trial in Dry AMD Terminated
5.5.3 Soliris (Alexion): Out of the Running?
5.6 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
5.6.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Insert in Phase 2
5.6.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
5.7 Neuroprotection: One of Modern Medicine’s Holy Grails
5.7.1 Tandospirone (Alcon): No News on Serotonin 1A Agonist
5.7.2 NT-501 (Neurotech): Some Promising Data in Dry AMD Studies
5.7.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
5.7.4 RN6G (Pfizer): Amyloid Beta-Binding Monoclonal Antibody Still in Studies
5.7.5 VAR10200 (Varinel): A Preclinical Candidate to Watch
5.8 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
5.8.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
5.8.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
5.8.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
5.8.4 Biotime: Stem Cell leader with Dry AMD Interests
5.8.5 First iPSC Trial in Japan in Dry AMD Patients
5.8.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
5.9 Other Treatments for Dry AMD
6. Diabetic Retinopathy Segment, 2014-2025
6.1 Segment to Grow in Importance as Diabetes Epidemic Continues
6.2 DR Options Grow with DME Addressed by New Agents
6.3 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
6.4 Lucentis: The Game Changer for DR?
6.5 New Anti-VEGF Additions
6.5.1 Is Eylea Better than Lucentis and Avastin for DME?
6.6 Steroids in Development for DR
6.6.1 Iluvien (Alimera/pSivida): New Option in European Markets
6.6.2 A New Hope? Optina (Ampio Pharmaceuticals)
6.6.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
6.6.4 SK-0503 (Sanwa Kagaku Kenkyusho): Potential DME and BRVO Treatment
6.6.5 Cortiject (Santen): Prodrug Candidate
6.6.6 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
6.7 Other Products in Development for DR
6.7.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
6.7.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
6.7.3 TriLipix (Abbott): No New Development for Promising Drug
6.7.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
6.7.5 Darapladib (GlaxoSmithKline): Possible New Use for Atherosclerosis Drug
6.7.6 Jetrea (ThromboGenics/Novartis): Possibilities in DME?
7. Regional Market Breakdown, 2014-2025
7.1 Which Markets Hold the Most Revenue Growth Potential?
7.2 The US: Leading Market for Retinal Diseases
7.3 Japan: Strong Market Potential
7.4 EU5: Ageing Populations to Drive Market Growth
7.5 BRIC Nations: The Biggest Growth Driver for the Market
8. Qualitative Industry and Market Analysis, 2015-2025
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation for the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Challenges
9. Research Interviews
9.1 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 1)
9.1.1 MC-1101: Identifying and Treating Chiou Syndrome
9.1.2 Preventing Dry AMD Progression
9.1.3 Treating the Root Cause of Dry AMD
9.1.4 Phase 3: Endpoints and Prospects for MC-1101
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 2)
9.2.1 MC-1101: Progress in Clinical Trials
9.2.2 MC-1101 More Effective in Early to Mid-Range AMD
9.2.3 Partnerships and Expected Launch of MC-1101
10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
List of Tables
Table 1.1 Submarket Forecasts ($m) of AMD and Other Retinal Disease Therapies, 2014-2019
Table 1.2 Submarket Forecasts ($m) of AMD and Other Retinal Disease Therapies, 2019-2025
Table 1.3 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 2.3 Market Breakdown by Product: Revenues ($m), Market Share (%), 2013
Table 2.4 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2013
Table 2.5 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2014
Table 2.6 Retinal Diseases Market Forecasts by Segment: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 2.7 Retinal Diseases Market Forecasts by Segment: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 2.8 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2019
Table 2.9 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2025
Table 3.1 Market Forecast by Leading Product: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.2 Market Forecast by Leading Product: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.3 Market Breakdown by Product: Revenues ($m), Market Share (%), 2019
Table 3.4 Market Breakdown by Product: Revenues ($m), Market Share (%), 2025
Table 3.5 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
Table 3.6 Lucentis: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.7 Lucentis: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.8 Eylea Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.9 Eylea Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.10 Avastin Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.11 Avastin Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.12 Visudyne Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.13 Visudyne Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.14 Jetrea Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.15 Jetrea Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 4.1 Wet AMD Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.2 Wet AMD Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2025
Table 4.3 Selected R&D Pipeline for wAMD, 2014
Table 5.1 Dry AMD Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 5.2 Dry AMD Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2025
Table 5.3 Selected R&D Pipeline for Dry AMD, 2014
Table 6.1 DR Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 6.2 DR Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2025
Table 6.3 Selected R&D Pipeline for DR, 2014
Table 7.1 Regional Breakdown: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 7.2 Regional Breakdown: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 7.3 EU5 Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 7.4 EU5 Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 7.5 BRIC Nations Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 7.6 BRIC Nations Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 8.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2015
Table 8.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2015
Table 8.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2015-2025
List of Figures
Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenues ($m), 2014-2025
Figure 2.2 Market Breakdown by Product Revenues ($m), Market Share (%), 2013
Figure 2.3 Market Breakdown by Company: Market Share (%), 2013
Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 2.6 Market Breakdown by Disease Segment: Revenues ($m), 2013
Figure 2.7 Wet AMD Disease Segment: Market Share (%), 2013
Figure 2.8 Dry AMD Disease Segment: Market Share (%), 2013
Figure 2.9 DR Disease Segment: Market Share (%), 2013
Figure 2.10 Other Retinal Diseases Segment: Market Share (%), 2013
Figure 2.11 Market Breakdown by Disease Segment: Market Share (%), 2019
Figure 2.12 Market Breakdown by Disease Segment: Market Share (%), 2025
Figure 2.13 Retinal Diseases Market Breakdown by Segment: Revenues ($m), 2014-2025
Figure 2.14 Retinal Diseases Market Breakdown by Segment: Revenues ($m), 2013, 2019 and 2025
Figure 3.1 Market Breakdown by Product: Revenues ($m), Market Share (%), 2019
Figure 3.2 Market Breakdown by Product: Revenues ($m), Market Share (%), 2025
Figure 3.3 Market Forecast by Product: Revenues ($m), 2014-2025
Figure 3.4 Market Breakdown by Product: Revenues ($m), 2013, 2019 and 2025
Figure 3.5 Drivers and Restraints for Lucentis, 2014
Figure 3.6 Lucentis: Revenues Forecast ($m), 2014-2025
Figure 3.7 Drivers and Restraints for Eylea, 2014
Figure 3.8 Eylea Forecast: Revenues ($m), 2014-2025
Figure 3.9 Drivers and Restraints for Avastin, 2014
Figure 3.10 Avastin Forecast: Revenues ($m), 2014-2025
Figure 3.11 Visudyne Forecast: Revenues ($m), 2014-2025
Figure 3.12 Jetrea Forecast: Revenues ($m), 2014-2025
Figure 4.1 Wet AMD Segment Forecast: Revenues ($m), 2014-2025
Figure 5.1 Dry AMD Segment Forecast: Revenues ($m), 2014-2025
Figure 6.1 DR Segment Forecast: Revenues ($m), 2014-2025
Figure 7.1 Regional Breakdown: Revenues ($m), 2014-2025
Figure 7.2 Regional Breakdown: Revenues ($m), 2013, 2019 and 2025
Figure 7.3 Regional Market Share (%), 2013
Figure 7.4 Regional Market Share (%), 2019
Figure 7.5 Regional Market Share (%), 2025
Figure 7.6 US Market: Revenues ($m), 2014-2025
Figure 7.7 Japan: Revenues ($m), 2014-2025
Figure 7.8 EU5: Grouped Revenues ($m), 2014-2025
Figure 7.9 EU5 Breakdown: Revenues ($m), 2013-2025
Figure 7.10 EU5 Breakdown: Market Share (%), 2013
Figure 7.11 EU5 Breakdown: Market Share (%), 2019
Figure 7.12 EU5 Breakdown: Market Share (%), 2025
Figure 7.13 BRIC Nations Forecast: Revenues ($m), 2014-2025
Figure 7.14 BRIC Nations Forecasts: Revenues ($m), 2014-2025
Figure 7.15 Market Share (%) within BRIC Group by Country, 2013
Figure 7.16 Market Share (%) within BRIC Group by Country, 2019
Figure 7.17 Market Share (%) within BRIC Group by Country, 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook